王瑜珺，中国科学院上海药物研究所研究员、课题组长。2003年6月毕业于沈阳药科大学药物制剂专业，2009年6月通过沈阳药科大学和中国科学院上海药物研究所联合培养获得药理学博士学位。2009年9月至2013年3月在美国天普大学药理系和物质滥用研究中心进行博士后训练，从事阿片受体功能和成瘾机制研究。<\/font><\/div>\n

长期从事阿片受体功能、成瘾机制研究和低成瘾性镇痛药、戒毒药开发。研究工作揭示了阿片类物质引起奖赏效应和戒断后负性强化的分子机制，以研究中发现的kappa受体为靶标，合作开发了多个低中枢副作用的镇痛先导化合物。在Molecular Psychiatry，Embo Molecular Medicine，Cell Reports，Journal of Neuroscience和Journal of Medicinal Chemistry<\/i><\/font>等期刊发表论文47篇，以第一\/通讯（含共同）作者论文27篇。申请国内发明专利4项，授权1项。2018年获“中国药理学会青年药理学家奖”，2018年获“SA-SIBS优秀青年科技人才奖励”，2017年入选中国科学院青年创新促进会，2016年入选中科院上海药物所“新星计划”。曾获得江苏省科学技术二等奖。受2030“脑科学与类脑研究”重大项目、国家自然科学基金面上项目、青年项目、上海市自然科学基金面上项目、中国科学院青年创新促进会和中国科学院上海药物所“新星计划”资助。<\/font><\/div>\n

\n<\/b><\/font><\/div>\n
教育经历：<\/font><\/b><\/div>\n
2009.09-2013.03 美国天普大学药理系和物质滥用研究中心，神经药理博士后<\/font><\/div>\n
2004.09-2009.06 沈阳药科大学与中科院上海药物所联合培养，神经药理博士<\/font><\/div>\n
1999.09-2003.06 沈阳药科大学，药物制剂学士<\/font><\/div>","yjfx":"
1. 阿片受体功能研究<\/div>\n
2. 成瘾的神经生物学机制研究和低成瘾性镇痛药、戒毒药开发<\/div>\n
3. 疼痛和抑郁等神经精神疾病的新靶标发现和创新药物研究<\/div>\n <\/b>","dblz":"
1.Wang YJ<\/b>#*, Yu C#, Wu WW#, Ju YY, Liu Y, Xu C, Long JD, Zan GY, Wei XY, Zhang LS, Chai JR, Chen Z*, Liu JG*. Alteration of twinfilin1 expression underlies opioid withdrawal-induced remodeling of actin cytoskeleton at synapses and formation of aversive memory. Mol Psychiatry <\/i>2021. <\/font><\/div>\n
2.Chen ZG#, Wang YJ<\/b>#, Chen RS#, Geng F, Gan CL, Wang WS, Liu X, Zhou H, He L, Hu G*, Liu JG*. Ube2b-dependent degradation of DNMT3a relieves a transcriptional brake on opiate-induced synaptic and behavioral plasticity. Mol Psychiatry<\/i> 2021, 26:1162-1177. <\/font><\/div>\n
3.Zan GY#, Wang YJ<\/b>#*, Li XP#, Fang JF, Yao SY, Du JY, Wang Q, Sun X, Liu R, Shao XM, Long J D, Chai JR, Deng YZ, Chen YQ, Li QL, Fang JQ, Liu ZQ*，Liu JG*. Amygdalar κ-opioid receptor-dependent upregulating glutamate transporter 1 mediates depressive-like behaviors of opioid abstinence. Cell Rep <\/i>2021, 37, 109913, doi:10.1016\/j.celrep.2021.109913.<\/font><\/div>\n
4.Zhang L#, Kibaly C#, Wang YJ<\/b>#, Xu C, Song KY, McGarrah PW, Loh HH, Liu JG*, Law PY*. Src-dependent phosphorylation of mu-opioid receptor at Tyr(336) modulates opiate withdrawal. EMBO Mol Med<\/i> 2017, 9:1521-1536. <\/font><\/div>\n
5.Kong LH, Shu X, Tang S, Ye R, Sun H, Jiang S, Li Z, Chai J, Fang Y, Lan Y, Yu L, Xie Q, Fu W, Wang YJ<\/b>*, Li W*, Qiu Z, Liu JG*, Shao L*. SLL-627 is a highly selective and potent k opioid receptor (KOR) agonist with an Unexpercted Noreduction in Locomotor activity. J Med Chem<\/i>, 2022. 65 (15), 10377-10392<\/font><\/div>\n
6.He Q, Wei Y, Liu X, Ye R, Kong L, Li Z, Jiang S, Yu L, Chai J, Xie Q, W, Wang YJ*<\/b>, Li W*, Qiu Z, Liu JG*, Shao L*. Discovery of an m substituted N cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaine as a selective, potent, and orally active κ opioid receptor agonist with an improved central nervous system safety profile. J Med Chem<\/i> 2021, 64(16), 12414–12433. <\/font><\/div>\n
7.Huang H#, Li X#, Xie P#, Li X, Xu X, Qian Y, Yuan C, Meng X, Chai J, Chen J, Liu J, Wang W, Li W*, Wang Y<\/b>*, Fu W*, Liu JG. (2021) Discovery, Structure-Activity Relationship and Mechanism Studies of 1-((3R, 4S)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one as Novel Potent Analgesic. J Med Chem<\/i> 2021 Accepted <\/font><\/div>\n
8.Xiao L#, Wang Y#, Zhang M#, Wu W#, Kong L, Ma Y, Xu X, Liu X, He Q, Qian Y, Sun H, Wu H, Lin C, Huang H, Ye R, Jiang S, Ye RF, Yuan C, Fang S, Xue D, Yang X, Chen H, Zheng Y, Yu L, Xie Q, Zheng L, Fu W, Li W*, Qiu Z, Liu J*, Shao L*. Discovery of a Highly Selective and Potent kappa Opioid Receptor Agonist from N-Cyclopropylmethyl-7alpha-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message-Address Concept. J Med Chem<\/i> 2019, 62:11054-11070. <\/font><\/div>\n
9.Lu YC; Wang YJ<\/b>*; Lu B; Chen M; Zheng P; Liu JG*. ACC to Dorsal Medial Striatum Inputs Modulate Histaminergic Itch Sensation. Journal of Neuroscience<\/i>, 2018, 38(15): 3823-3839<\/font><\/div>\n
10.Tao YM#, Yu C#, Wang WS, Hou YY, Xu XJ, Chi ZQ, Ding YQ, Wang YJ<\/b>*, Liu JG*. Heteromers of mu opioid and dopamine D1 receptors modulate opioid-induced locomotor sensitization in a dopamine-independent manner. Br J Pharmacol <\/i>2017, 174:2842-2861. <\/font><\/div>\n
11.Deng YZ, Lu YC, Wu WW, Cheng L, Zan GY, Chai JR, Wang YJ<\/b>*, Chen Z, Liu JG. Anteromedial thalamic nucleus to anterior cingulate cortex inputs modulate histaminergic itch sensation. Neuropharmacology<\/i> 2020, 168:108028 <\/font><\/div>\n
12.Wang YJ<\/b>, Hang A, Lu YC, Long Y, Zan GY, Li XP, He L, Chi ZQ, Liu JG. Opioid receptor activation in different brain regions differentially modulate anxiety-related behaviors in mice. Neuropharmacol<\/i>, 2016, doi: 10.1016\/j.neuropharm.2016.04.022. <\/font><\/div>\n
13.Zhang LS#, Wang YJ#<\/b>, Ju YY, Zan GY, Xu C, Hong MH, Wang YH, Chi ZQ, Liu JG. Role for engagement of β-arrestin 2 by the transactivated EGFR in agonist-specific regulation of δ receptor activation of ERK1\/2. Brit J Pharmacol<\/i>, 2015, 172(20):4847-4863<\/font><\/div>\n
14.Wang YJ<\/b>, Huang P, Blendy J and Liu-Chen LY. Brain region- and sex-specific alterations of DAMGO-stimulated [35S]GTPgS binding in mice with Oprm1 A112G. Addict. Biol,<\/i> 2012. doi: 10.1111\/j.1369-1600.2012.00484.x<\/font><\/div>\n
15.Wang YJ<\/b>, Huang P, Ung A, Blendy J and Liu-Chen LY. Reduced expression of the mu opioid receptor in some, but not all, brain regions in mice with Oprm1 A112G. Neuroscience<\/i>, 2012, 205:178-84.<\/font><\/div>\n
16.Wang YJ<\/b>, Rasakham K, Huang P, Chudnovskaya D, Cowan A, Liu-Chen L-Y. Sex difference in kappa opioid receptor (KOPR)-mediated behaviors and brain region KOPR level and KOPR-mediated [35S]GTPgS binding in the guinea pig. J Pharmacol Exp Ther<\/i>, 2011, 339:438-450.<\/font><\/div>\n
17.Wang YJ<\/b>, Tao YM, Li FY, Wang YH, Xue XJ, Chen J, Cao YL, Chi ZQ, Neumeyer JL, Zhang A, Liu-JG. Pharmacological characterization of ATPM, a novel mixed κ agonist and μ agonist\/antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. J Pharmacol Exp Ther,<\/i> 2008. 329(1): 306-13<\/font><\/div>\n
18.Lin X#, Wang YJ<\/b>#, Li Q, Hou YY, Hong MH, Cao YL, Chi ZQ, Liu JG. Chronic high-dose Morphine treatment Promotes SH-SY5Y Cell Apoptosis via c-Jun N-terminal kinase-mediated activation of mitochondria-dependent pathway. FEBS J,<\/i> 2008, 276(7): 2022-36<\/font><\/div>\n
<\/div>","jyjl":"","gzjl":"
\n
2023.02-至今<\/label>\n
中国科学院上海药物研究所\/中科环渤海（烟台）药物高等研究院，课题组长、研究员<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n
\n
2020.11-2022.12<\/label>\n
中国科学院上海药物研究所，研究员<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n
\n
2015.11-2020.10<\/label>\n
中国科学院上海药物研究所，副研究员<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>\n
\n
2013.06-2015.10<\/label>\n
中国科学院上海药物研究所，助理研究员<\/div>\n<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n<\/li>","ktxm":"
2020.07-2023.06 <\/b>上海市自然科学基金面上项目，丘脑前内侧核介导的丘脑皮层通路在痒觉中的调控作用及其机制研究，项目负责人<\/div>\n
2018.01-2021.12 <\/b>国家自然科学基金面上项目，Kappa受体激活介导谷氨酸转运体表达异常在社交逃避抑郁样行为中的作用及机制研究，项目负责人<\/div>\n
2017.01-2020.12 <\/b>中国科学院青年创新促进会，成瘾的神经生物学机制，项目负责人<\/div>\n
2015.01-2017.12 <\/b>国家自然科学基金青年基金，Src酪氨酸激酶在吗啡依赖中的调节作用及机制研究，项目负责人<\/div>","ryhj":"
2016年入选中国科学院上海药物所“新星计划” <\/font><\/div>\n
2017年入选中国科学院青年创新促进会<\/font><\/div>\n
2018年获“中国药理学会青年药理学家奖”<\/font><\/div>\n
2018年获“SA-SIBS优秀青年科技人才奖励”<\/font><\/div>\n
2020年获江苏省科学技术二等奖<\/font><\/div>","xpwj":"http://sourcedb.simm.cas.cn/zw/gb2020/yjzz/202305/P020230508553342987864.jpg","kycg":"
1. 揭示了局部脑区神经元突触结构重塑在吗啡成瘾记忆形成中的作用及调控机制。<\/div>\n
2. 揭示了强啡肽\/kappa阿片受体系统在编码负性情绪中的作用及涉及的分子机制和神经环路。<\/div>\n
3. 以kappa受体为靶标开发了多个镇痛、止痒和戒毒先导化合物。<\/div>\n
<\/div>","shrz":"
上海市生理科学会理事<\/div>\n
中国药物滥用防治协会成瘾与脑科学分会常委<\/div>\n
中国药理学会生化和分子药理学会委员<\/div>\n
Advances in Drug and Alcohol Research (ADAR)，Associate Editor <\/div>\n
沈阳药科大学学报编委<\/div>\n
中国药理学通报青年编委<\/div>","puburl":"http://sourcedb.simm.cas.cn/zw/gb2020/yjzz/202305/t20230508_6750321.json"});